Pentixapharm to Present Pioneering Bladder Cancer Treatment at ASCO-GU 2025

Pentixapharm Holding AG will present first-in-human data on the treatment of muscle-invasive bladder cancer (MIBC) using their innovative Lu177-PentixaTher compound at ASCO-GU 2025 in San Francisco. The study highlights a late-stage MIBC patient who achieved a complete response following a combination of chemotherapy and intravesical instillation of Lu177-PentixaTher, targeting the CXCR4 receptor.

The promising results suggest potential bladder preservation due to the precision of the instillation therapy. With reduced systemic exposure, it decreases adverse effects. These findings contribute to the evidence supporting CXCR4 as a viable target in oncology.

More than 100 patients have benefited from PentixaTher, and the company is advancing clinical trials, including a Phase I/II trial for leukemia in France. The ASCO-GU presentation will be given by Dr. Ralph Wirtz on February 14, 2025.